• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adc Therapeutics Sa (NY: ADCT )

    3.120 -0.030 (-0.95%)
    Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 256,805
    Open 3.160
    Bid (Size) 3.030 (2)
    Ask (Size) 3.270 (7)
    Prev. Close 3.150
    Today's Range 2.990 - 3.160
    52wk Range 0.3599 - 6.040
    Shares Outstanding 76,721,543
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire

    Performance

    YTD
    +84.62%
    +84.62%
    1 Month
    +14.29%
    +14.29%
    3 Month
    -15.22%
    -15.22%
    6 Month
    -29.73%
    -29.73%
    1 Year
    +278.55%
    +278.55%

    More News

    Read More
    ADC Therapeutics to Present at Upcoming Investor Conferences
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    7 Growth Stocks to Buy for Under $5 for Massive Gains
    Via InvestorPlace
    Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
    From ADC Therapeutics SA
    Via GlobeNewswire
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Via InvestorPlace
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
    From ADC Therapeutics SA
    Via GlobeNewswire
    ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
    From ADC Therapeutics SA
    Via GlobeNewswire
    Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    From ADC Therapeutics SA
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.